Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,124 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza Virus Vaccine Clear all
Completed Not applicable Interventional

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

NCT01713855
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura
Interventions
Inactivated Trivalent Influenza vaccine
Biological
Lead sponsor
Neufeld, Ellis J, MD, PhD
Individual
Eligibility
18 Months to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 14, 2026, 4:30 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A/Texas Flu Challenge

NCT06753474
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus influenza A H3N2 strain
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

NCT00645411
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV)
Biological
Lead sponsor
Novartis
Industry
Eligibility
3 Years to 17 Years
Enrollment
3,604 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
16
States / cities
Fayetteville, Arkansas • Downey, California • Bardstown, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 1 Interventional

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

NCT00056758
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous Dendritic Cell HIV Vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2007 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flu Shot Pre-visit Questionnaire

NCT05508698
View directory record Official record
Conditions
Influenza
Interventions
Precommitment Nudge, Salience
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
230,962 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 14, 2026, 4:30 AM EDT
Completed No phase listed Observational

Respiratory Virus Hospitalization Study (FLU 003 Plus)

NCT01056185
View directory record Official record
Conditions
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
18
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 14, 2026, 4:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry

NCT02554409
View directory record Official record
Conditions
Pregnancy, Influenza
Interventions
Quadrivalent Intradermal Influenza Vaccine (QIV)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Albany, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Texas 2017 (H3N2) Challenge Study

NCT06476275
View directory record Official record
Conditions
Influenza Viral Infections
Interventions
Influenza A/Texas/71/2017 (H3N2), Sham placebo
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 46 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 4 Interventional Results available

Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals

NCT01262846
View directory record Official record
Conditions
HIV Infection
Interventions
Fluzone®
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

NCT03179761
View directory record Official record
Conditions
Hematopoietic Cell Transplantation
Interventions
Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

NCT01162122
View directory record Official record
Conditions
Influenza
Interventions
MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV)
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
65 Years and older
Enrollment
7,109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Phoenix, Arizona • DeLand, Florida • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Not applicable Interventional

Electronic Health Records for Health Promotion

NCT00142077
View directory record Official record
Conditions
Influenza
Interventions
Electronic health record and messaging system
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2007 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

NCT00992836
View directory record Official record
Conditions
HIV Infections, H1N1 Influenza Virus
Interventions
Influenza A (H1N1) 2009 monovalent vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years

NCT00995982
View directory record Official record
Conditions
Influenza, Human
Interventions
VRC-FLUDNA056-00VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
45 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

NCT06097273
View directory record Official record
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
8,061 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
146
States / cities
Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 14, 2026, 4:30 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Influenza Challenge in Mood Disorders

NCT02415166
View directory record Official record
Conditions
MAJOR DEPRESSIVE DISORDER
Interventions
INFLUENZA VACCINE, NaCl-saline placebo
Biological · Other
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

NCT01674205
View directory record Official record
Conditions
Influenza, Human
Interventions
A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca), A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca), 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®), Vaccine placebo (Leibovitz-15 [L-15]), Vaccine placebo (FluMist®)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

NCT01776554
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
6 Months to 17 Years
Enrollment
662 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Miami, Florida • Newton, Kansas • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02563093
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

NCT06124131
View directory record Official record
Conditions
Health Behavior, Colorectal Cancer, Influenza, COVID-19, Vaccine Hesitancy, Vaccine-Preventable Diseases, Healthcare Patient Acceptance
Interventions
Financial incentive for colorectal cancer screening, Financial incentive for flu shot, Financial incentive for COVID-19 shot
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
45 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 4 Interventional Results available

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

NCT02787044
View directory record Official record
Conditions
Heart Failure, Myocardial Infarction
Interventions
High Dose Trivalent Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 93 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

NCT02285998
View directory record Official record
Conditions
Influenza
Interventions
Flublok Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
9,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Tempe, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

NCT01250795
View directory record Official record
Conditions
Healthy
Interventions
HAI-05 Influenza Vaccine, Saline
Biological · Other
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Wichita, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 14, 2026, 4:30 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza

NCT00706732
View directory record Official record
Conditions
Influenza
Interventions
AVX502, Placebo
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 14, 2026, 4:30 AM EDT